These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17549053)

  • 1. Treatment of refractory chronic GVHD with rituximab: a GITMO study.
    Zaja F; Bacigalupo A; Patriarca F; Stanzani M; Van Lint MT; Filì C; Scimè R; Milone G; Falda M; Vener C; Laszlo D; Alessandrino PE; Narni F; Sica S; Olivieri A; Sperotto A; Bosi A; Bonifazi F; Fanin R;
    Bone Marrow Transplant; 2007 Aug; 40(3):273-7. PubMed ID: 17549053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
    von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
    Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation.
    Atsuta Y; Suzuki R; Yamamoto K; Terakura S; Iida H; Kohno A; Naoe T; Yano K; Wakita A; Taji H; Hamaguchi M; Kodera Y; Sao H; Morishima Y; Hamajima N; Morishita Y
    Bone Marrow Transplant; 2006 Feb; 37(3):289-96. PubMed ID: 16400341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
    Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
    Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of budesonide mouthwash on oral chronic graft versus host disease.
    Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
    Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.
    Andree H; Hilgendorf I; Leithaeuser M; Junghanss C; Holzhueter S; Loddenkemper C; Steiner B; Freund M; Wolff D
    Bone Marrow Transplant; 2008 Oct; 42(8):541-6. PubMed ID: 18641680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.
    Foss FM; DiVenuti GM; Chin K; Sprague K; Grodman H; Klein A; Chan G; Stiffler K; Miller KB
    Bone Marrow Transplant; 2005 Jun; 35(12):1187-93. PubMed ID: 15852025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective review of the outcome after second or subsequent allogeneic transplantation.
    Kedmi M; Resnick IB; Dray L; Aker M; Samuel S; Gesundheit B; Slavin S; Or R; Shapira MY
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):483-9. PubMed ID: 19285636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.